Lu177‐PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution
- 22 April 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 65 (6) , 740-747
Abstract
Introduction: Radioligand therapies, or ‘theranostics’, have an emerging role in patients with metastatic castration‐resistant prostate cancer (mCRPC). Lutetium‐177 (Lu), targeting prostate‐specific membrane antigen (PSMA), has demonstrated promising outcomes including reduced disease progression and improved overall survival. We aim to determine overall survival demonstrated by our LuPSMA patient cohort to date.Methods: Kaplan–Meier survival analysis and log‐rank test were performed on all LuPSMA therapy patients with at least 12 months of follow‐up data available (n = 68). Comparison across patients was made based on several variables including the baseline characteristics of prostate‐specific antigen (PSA) level, maximum standard uptake value (SUVmax) and metastasis site and by biochemical response.Results: The 18‐month overall survival estimate for the patient cohort was 63.8%. Patients with baseline serum PSA P < 0.05). Patients with an SUVmax >15 had an 18‐month survival estimate of 56.0%, compared to 38.0% in patients with SUVmax ≤15 (P < 0.05). No significant difference in overall survival was observed by metastasis site. Both a decrease in PSA after two LuPSMA therapy cycles and the maximum response over the treatment course being a decline in PSA were indicative of greater overall survival (P < 0.01 and P < 0.001 respectively).Conclusion: Our study reported an 18‐month overall survival of 64% in patients with mCRPC who have undergone LuPSMA therapy. Our study identified that baseline serum PSA, SUVmax and biochemical response to treatment are prognostic markers for increased overall survival.Keywords
This publication has 17 references indexed in Scilit:
- Lu177‐PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institutionJournal of Medical Imaging and Radiation Oncology, 2019
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990–2015: findings from the Global Burden of Disease Study 2015Cancer Epidemiology, 2018
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013Journal of Nuclear Medicine, 2016
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancerOncotarget, 2016
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617Journal of Nuclear Medicine, 2016
- Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Understanding survival analysis: Kaplan-Meier estimateInternational Journal of Ayurveda Research, 2010